Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.916 USD | +5.41% | +3.19% | +23.82% |
Mar. 06 | Canaccord Genuity Adjusts Cara Therapeutics Price Target to $10 From $11, Maintains Buy Rating | MT |
Mar. 04 | Transcript : Cara Therapeutics, Inc., Q4 2023 Earnings Call, Mar 04, 2024 |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+23.82% | 47.5M | |
+0.44% | 90.27B | |
+9.61% | 44.05B | |
-16.88% | 31.45B | |
+44.99% | 23.35B | |
-9.27% | 16.72B | |
-25.92% | 15.09B | |
-9.38% | 12.82B | |
-7.57% | 11.95B | |
+0.07% | 8.71B |
- Stock
- Equities
- Stock Cara Therapeutics, Inc. - Nasdaq
- News Cara Therapeutics, Inc.
- Transcript : Cara Therapeutics, Inc., Q3 2021 Earnings Call, Nov 08, 2021